Introduction {#S1}
============

Excess adiposity has in general been associated with both increased cardiovascular (CV) disease and all-cause mortality ([@B7]). Nonetheless, the link between obesity and mortality has recently been disputed ([@B42]). Body mass index (BMI), the most widely used measure of adiposity, may not be the most reliable tool to predict CV and metabolic risk because it does not differentiate between fat and lean mass or give an indication of fat distribution, i.e., visceral vs subcutaneous ([@B1]). Many studies have demonstrated that excessive truncal or android fat (abdominal or visceral fat) may be the driving force behind increased CV disease development and progression to type-2 diabetes ([@B46]).

Increased android fat has been shown to be more closely associated with a clustering of metabolic syndrome components compared to gynoid fat in elderly people ([@B16]). Android fat is strongly correlated with serum lipids in population studies ([@B27]) and is associated with insulin resistance and diabetes in aging adults ([@B32]). On the other hand, accumulation of fat in the lower body (gluteofemoral or gynoid regions) is associated with a more favorable lipid ([@B27]) and glucose profile as well as a decrease in CV and metabolic disease prevalence after adjustment for total body mass ([@B38]).

Studies in younger populations have also demonstrated that android fat was more closely related to metabolic risk factors. For instance, the android/gynoid ratio was the obesity measure most closely related to both insulin resistance and dyslipidemia in children 7--13 years old ([@B37]) and intra-abdominal fat was the most important component of the body fat for multiple metabolic risk factors in a group of young adults ([@B43]).

In addition to the metabolic consequences accompanying excess adiposity, we showed that being overweight was associated with decreased endothelial, renal and cardiac function suggestive of early markers of CV risk in young healthy adults ([@B22]). Whether overweight-induced early organ damage is more related to android fat is unsure because this issue has not been investigated in detail. In middle aged subjects, android fat was found to be a determinant of arterial stiffness independent of traditional risk factors ([@B8]) and in a large study of subjects drawn from the general population, the trunk/body fat mass ratio was a predictor of early decline in kidney function ([@B29]). However, these studies included mostly lean participants, hence it remains uncertain as to whether early organ damage are more related to the presence of android fat in the overweight/obese setting.

Morphological and functional heterogeneity among adipose depots, together with genetic and environmental factors may contribute to differential cardiometabolic risk ([@B11]). Of note is the fact that sympathetic overdrive ([@B22]) and elevated concentration of serum uric acid (UA) ([@B24]) are important drivers of early CV risk indices in overweight subjects. Sympathovagal imbalance in the form of sympathetic overactivity and/or vagal withdrawal has been recognized as the central pathophysiological mechanism involved in the genesis of obesity. Sympathovagal imbalance has been reported to be the potential contributor to the obesity related co-morbidities such as diabetes, insulin resistance, hypertension, dyslipidemia and CV dysfunctions ([@B14]). Sympathetic nervous system overactivity is likely to negatively impact on glucose metabolism, lipid profile, blood pressure and end organ damage ([@B22]; [@B9]). [@B3], [@B2] showed that for the same level of BMI and total fat mass, subjects with high abdominal visceral fat have higher muscle sympathetic nerve activity (MSNA) compared to those with lower abdominal fat mass, while subcutaneous obesity was not associated with elevated sympathetic tone. Such sympathetic activation occurring preferentially in relation to the abdominal fat level may be an important link between abdominal obesity and the development of CV risk although this remains to be investigated. Serum UA has recently emerged as an important independent risk factor for increased CV disease ([@B5]) and was found to be associated with endothelial dysfunction, arterial stiffness and decreased renal function in individuals free of CV disease ([@B24]). Some studies have suggested that increased serum UA may be more pronounced in subjects with increased visceral adiposity ([@B18]; [@B49]) which may impact the CV risk profile.

Whether fat distribution is an important determinant of CV risk in young healthy overweight individuals and whether this is associated with autonomic nervous activity (sympathetic and vagal function) and serum UA remains uncertain. We hence evaluated the metabolic profile, end organ damage (renal, endothelial function and augmentation index), sympathetic nerve activity and serum UA concentration in healthy overweight men with low and high level of android fat.

Materials and Methods {#S2}
=====================

Subject Selection {#S2.SS1}
-----------------

The current study subjects (*n* = 46) participated in a previous clinical investigation ([@B25]). They were all male and were recruited through two major universities in the Melbourne metropolitan area. Participants fulfilled the following criteria: BMI ≥25 kg/m^2^ and aged between 18 and 30 years. They were non- smokers and not on any medication. None of the participants had a history of CV, metabolic or cerebrovascular disease. The Alfred Hospital Human Ethics Committee approved the study protocol and all subjects gave written informed consent before participating in the study.

Clinical Assessment {#S2.SS2}
-------------------

Participants were studied in the morning after an overnight fast. There were allowed one drink of water in the morning.

Demographic details of age, gender, race, clinical status and blood pressure were obtained from standard measurements and questionnaires. A detailed history and physical examination were conducted to exclude obesity and CV related comorbidities. Supine blood pressure was measured 3 times after 5 minutes rest using a Dinamap monitor (Model 1846SX, Critikon Inc., Tampa, FL, United States) and values were averaged. Body weight was measured in light indoor clothes without shoes using a digital scale. Waist circumference was measured at the midpoint between the lowest rib and iliac crest, and hip circumference at the level of the greater trochanters.

Endothelial Function and Augmentation Index {#S2.SS3}
-------------------------------------------

The endothelial function was assessed using the digital pulse amplitude measured in the fasting state with a pulse amplitude tonometry (PAT) device placed on the tip of each index finger (Itamar Medical Ltd.). PAT was assessed in response to reactive hyperemia. Measurements were obtained for 5 to 10 min at baseline followed by 5 min of occlusion of 1 arm, with the cuff inflated on the upper arm to suprasystolic pressure (60 mm Hg above systolic pressure or 200 mm Hg) and then released to induce reactive flow-mediated hyperemia, measured for 5 to 10 min. The PAT ratio was calculated as $\log_{e}{\lbrack{\frac{X_{ht}}{X_{h0}}/\frac{X_{ct}}{X_{c0}}}\rbrack}$, with "X" representing pulse amplitude, "h" denoting hyperemic finger, "c" denoting the control finger, "t" denoting the 30-s time interval between 1.5 min and 2.0 min post deflation, and "0" denoting baseline. This calculation was made independent of the automatic algorithm provided by Itamar Medical Ltd., and was implemented in endothelial function assessment in the Framingham Heart Study ([@B12]). The pulse amplitude waveform analysis of the PAT signal was used to derive a measure of arterial stiffness and was expressed as augmentation index (AI) normalized to a heart rate of 75 bpm (AI\@75).

Muscle Sympathetic Nerve Activity, Heart Rate, and Blood Pressure {#S2.SS4}
-----------------------------------------------------------------

Recording of multiunit postganglionic MSNA was made with participants resting in a supine position. A tungsten microelectrode (FHC, Bowdoin, ME, United States) was inserted directly into the right peroneal nerve just below the fibular head. A subcutaneous reference electrode was positioned 2--3 cm away from the recording site. The nerve signal was amplified (350,000), filtered (bandpass 700--2000 Hz), rectified and integrated. During MSNA recording, blood pressure was measured continuously using the Finometer system (Finapress Medical System BV, Enschede, Netherlands), and heart rate was determine using a three-lead echocardiogram. Blood pressure, electrocardiogram data, and MSNA were digitized with a sampling frequency of 1000 Hz (PowerLab recording system, model ML 785/8SP; ADI Instruments, Bella Vista, Australia). Resting measurements were recorded over a 15-min period and averaged. The MSNA was expressed as burst frequency (burst/min) and burst incidence (bursts/100 heartbeats). In addition, all of the participants underwent ambulatory BP monitoring over 24--26 h using an oscillometric monitor (model No. 90207, SpaceLabs Medical Inc., Snoqualmie, WA, United States) to measure brachial blood pressure and heart rate every 30 min. Blood pressure and heart rate values were averaged over the total period of the recording.

Spontaneous Cardiac Baroreflex Sensitivity {#S2.SS5}
------------------------------------------

Baroreflex sensitivity was assessed using the sequence method ([@B31]). The baroreflex efficacy index (BEI) and slope of the regression line between cardiac interval and systolic blood pressure was calculated for each validated sequence and averaged during a 15-min supine recording.

Heart Rate Variability {#S2.SS6}
----------------------

Heart rate variability (HRV) was assessed from the resting ECG recordings obtained during the MSNA recording and was determined using commercially available software (HRV Module for Chart 5 Pro; ADI Instruments, Bella Vista, Australia). Parameters derived were root mean square of successive R-R intervals (RMSSD) in the time domain analysis and Low Frequency (LF: 0.04--0.15 Hz) and High Frequency (HF: 0.15--0.4 Hz) in the frequency domain analysis expressed as normalized units.

Biochemistry and Metabolic Measurements {#S2.SS7}
---------------------------------------

Fasting blood samples were drawn from a cannula placed in an antecubital vein for biochemical analysis of creatinine, electrolytes, non-esterified fatty acids (NEFA), insulin, leptin, uric acid (UA), total cholesterol, triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), cholesterol, glucose, and liver enzymes alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT). A standard 75-g oral glucose tolerance test (OGTT) was performed and another blood sample was withdrawn 120 min post glucose administration (Glucaid, Fronine PTY, LTD., Taren Point Australia). Fasting insulin levels was measured as a surrogate index for insulin resistance as this has been shown to a reliable measure in healthy subjects ([@B20]).

The creatinine clearance was used to assess renal function. All the participants provided a 24-h urine collection on the day of the test. Creatinine clearance (*CCr*) was calculated using the following formula: *CCr*=(*U*~*Cr*~×*V*)/(*P*~*Cr*~), where "*U*~*Cr*~" is the creatinine concentration in urine, "*V*" the urine flow rate, and "*P*~*Cr*~" the creatinine concentration in plasma.

Lipidomic Analysis {#S2.SS8}
------------------

Lipidomic analysis was performed by liquid chromatography, electrospray ionization-tandem mass spectrometry using an Agilent 1290 liquid chromatography system with a 50x-mm Zorbax Eclipse Plus 1.8-mm C18 column combined with an Agilent 6490 mass spectrometer. The methods and lipid species within classes and subclasses analyzed have been described previously ([@B45]; [@B9]).

Body Composition {#S2.SS9}
----------------

Dual-energy X-ray absorptiometry scans were performed using Lunar iDXA (GE Health). Participants were wearing standard hospital gown. All jewelries were removed prior to the scan. The participants were lying down with their body fitted in the box outline on the iDXA table. All iDXA users were trained by the company with regards to correct placement. The iDXA unit was calibrated daily using the GE Health Lunar calibration phantom. Using this system, regional body composition precision error was previously reported to be less than 2.5% coefficient of variation for all regions except arms ([@B36]).

Total body, android and gynoid fat and lean masses were determined using the software provided by the manufacturer. The GE Healthcare systems define the android region as the area between the ribs and the pelvis that is totally enclosed by the trunk region. The gynoid region includes the hips and upper thighs and overlaps both the leg and trunk regions ([@B13]).

Data Analysis and Statistics {#S2.SS10}
----------------------------

The participants were divided into 2 groups (*n* = 23 each) according to the median value of the ratio of android fat to total body fat (%). Those above the median value (9.5%) were identified as "higher android fat content" and those below the value defined as "lower android fat content." Linear regression analysis was performed to assess the difference between the 2 groups of subjects. The model included the 2 quantiles of the ratio and was adjusted for BMI. We assessed the validity of the models by plotting the residuals against quantiles of the normal distribution.

All statistical analyses were performed using Stata 14.0 (StataCorp, 2015. College Station, TX, United States).

Results {#S3}
=======

The characteristics of the subjects are presented in [Table 1](#T1){ref-type="table"}. There was no difference in age and ethnicity between the 2 groups. Except for android fat mass, there was no significant difference in any other anthropometric measures between the 2 groups of subjects.

###### 

Age, ethnicity and body composition.

                                       **Lower android fat content (\<9.5% of total fat), *n* = 23**   **Higher android fat content (\>9.5% of total fat), *n* = 23**   ***P*-value**
  ------------------------------------ --------------------------------------------------------------- ---------------------------------------------------------------- ---------------
  Age, years                           23 ± 3                                                          23 ± 3                                                           0.799
  Ethnicity Asian/Caucasian (n)^(1)^   11/12                                                           14/9                                                             0.553
  Body mass, kg^(2)^                   94.0 (11.2)                                                     97.8 (33.5)                                                      0.517
  BMI, kg/m^2(2)^                      29.3 (3.8)                                                      30.7 (7.9)                                                       0.215
  Waist circumference, cm^(2)^         96.5 (13.5)                                                     105 (20.0)                                                       0.118
  Body fat,%                           32.4 ± 6.9                                                      35.7 ± 7.4                                                       0.150
  Total fat mass, kg^(2)^              29.4 (14.2)                                                     36.3 (18.1)                                                      0.103
  Total lean mass, kg                  60.8 ± 8.4                                                      60.8 ± 10.2                                                      0.981
  Android fat mass, kg^(2)^            2.4 (1.4)                                                       3.6 (2.1)                                                        0.005
  Gynoid fat mass, kg^(2)^             5.1 (1.5)                                                       4.9 (3.9)                                                        0.733

Data is reported as mean ± SD or median (interquartile range).

\(1\)

Chi-square with Yates correction,

\(2\)

Mann--Whitney test.

Hemodynamic Assessments {#S3.SS1}
-----------------------

Hemodynamic assessments are presented in [Table 2](#T2){ref-type="table"}. Systolic blood pressure and diastolic blood pressure as assessed either in the clinic or over a 24h period did not differ, but the heart rate was significantly higher in those with higher android fat content. Muscle sympathetic nerve activity (successful recordings in 45 subjects) as expressed in burst frequency was slightly higher in subjects with higher android fat (*p* = 0.04) but this significance was lost after adjustment for the heart rate (burst incidence, *p* = 0.68). Similarly, the slope and the BEI derived from the cardiac baroreflex function analysis were not different. None of the HRV parameters differed between the two groups.

###### 

Blood pressure, heart rate, muscle sympathetic nerve activity (MSNA), and cardiac baroreflex function.

                                               **Lower android fat content (\<9.5% of total fat)**   **Higher android fat content (\>9.5% of total fat)**   ***P*-value**
  -------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ---------------
  24-h systolic blood pressure, mmHg           120.0 ± 8.7                                           117.4 ± 8.2                                            0.324
  24-h diastolic blood pressure, mmHg          70.0 ± 7.0                                            71.4 ± 8.7                                             0.554
  24-h heart rate, bpm^(1)^                    67.5 (8.8)                                            72.0 (8.0)                                             0.048
  Clinic systolic blood pressure, mmHg         121.8 ± 12.6                                          120.6 ± 12.3                                           0.49
  Clinic diastolic blood pressure, mmHg        69.7 ± 6.3                                            73.0 ± 8.9                                             0.34
  Heart rate, bpm                              67.2 ± 8.7                                            76.2 ± 10.9                                            0.01
  MSNA, bursts per min                         28.7 ± 11.6                                           31 ± 13.4                                              0.04
  MSNA, bursts per 100 heartbeats              43.9 ± 16.0                                           44.3 ± 15.6                                            0.68
  Cardiac baroreflex function slope, ms/mmHg   31.2 ± 15.4                                           29.7 ± 20.4                                            0.766
  BEI                                          36.2 ± 13.9                                           32.4 ± 11.8                                            0.59
  Heart rate variability components                                                                                                                         
  RMSSD, ms^(1)^                               39.9 (25.9)                                           40.7 (25.9)                                            0.982
  LF (nu)                                      61.3 ± 16.9                                           61.3 ± 12.0                                            0.989
  HF (nu)                                      38.2 ± 16.1                                           37.3 ± 11.2                                            0.817
  LF:HF^(1)^                                   1.60 (1.29)                                           1.82 (1.20)                                            0.590

BEI, baroreflex efficacy index; RMSSD, root mean square of successive RR interval differences; LF, low frequency; HF, high frequency; nu, normalized units. Data is reported as mean ± SD or median (interquartile range).

\(1\)

Mann--Whitney test.

Metabolic Parameters {#S3.SS2}
--------------------

The fasting plasma glucose concentration was not different between subjects with lower and higher android fat content, however, 2-h plasma glucose concentration as well as fasting insulin concentration were higher in those with more android fat content ([Table 3](#T3){ref-type="table"}, *p* = 0.02, and *p* = 0.043, respectively). Serum UA was significantly higher in participants with higher android fat content (*p* \< 0.001). High sensitivity-CRP, NEFA and leptin plasma levels were not different. Lipid profile indicated higher plasma triglycerides concentration (*p* = 0.006) while total, HDL and LDL cholesterol did not differ. Lipidomic class analysis were performed in a subgroup of subjects (lower android fat: *n* = 21; higher android fat: *n* = 19). Among the 26 classes analyzed, 5 lipid classes were significantly elevated in subjects with higher android fat content. Those were: Ceramide (CER), Diacylglycerol (DG), phosphatidylethanolamine (PE), phosphatidylglycerol (PG) and triacylglycerol (TAG) ([Table 3](#T3){ref-type="table"}). Among the liver enzymes, ALT was slightly not but significantly higher in subjects with higher android fat content. GGT concentrations were elevated in those with higher android fat content compared to those with lower android fat content (*p* \< 0.05).

###### 

Biochemical data.

                               **Lower android fat content (\<9.5% of total fat)**   **Higher android fat content (\>9.5% of total fat)**   ***P-*value**
  ---------------------------- ----------------------------------------------------- ------------------------------------------------------ ---------------
  Fasting glucose, mmol/L      4.70 ± 0.35                                           4.64 ± 0.31                                            0.42
  2-h plasma glucose, mmol/L   4.99 ± 1.1                                            5.96 ± 1.3                                             0.02
  Insulin, mmol/L              17.7 ± 8.3                                            25.4 ± 11.7                                            0.043
  Total cholesterol, mmol/L    4.47 ± 0.67                                           4.84 ± 0.89                                            0.101
  HDL cholesterol, mmol/L      1.17 ± 0.22                                           1.08 ± 0.20                                            0.297
  LDL cholesterol, mmol/L      2.76 ± 0.60                                           2.89 ± 0.66                                            0.457
  Triglycerides, mmol/L        1.19 ± 0.6                                            1.9 ± 0.9                                              0.006
  h-CRP (mg/l)^(1)^            0.85 (2.38)                                           1.50 (1.60)                                            0.335
  ALT (U/L)^(1)^               30 (18)                                               38 (32)                                                0.072
  GGT (U/L)                    27.3 ± 13.7                                           45.3 ± 28.8                                            0.017
  NEFA,                        0.335 ± 0.166                                         0.414 ± 0.183                                          0.155
  Uric acid, mmol/L            0.376 ± 0.069                                         0.457 ± 0.076                                          \<0.001
  Leptin, ng/mL                21.9 ± 8.7                                            19.6 ± 12.3                                            0.568
  Lipidomic classes^(2)^                                                                                                                    
  Total CER, pmol/mL           6.1 ± 1.1                                             7.4 ± 2.3                                              0.027
  Total DG, pmol/mL            41.4 ± 2.3                                            79.6 ± 4.7                                             0.002
  Total PE, pmol/mL            20.6 ± 9.6                                            32.2 ± 1.7                                             0.012
  Total PG, pmol/mL            0.64 ± 0.1                                            0.94 ± 0.3                                             0.007
  Total TAG, pmol/mL           675 ± 217                                             994 ± 442                                              0.006

HOMA, homeostatic model assessment; CER, ceramide; DG, diacylglycerol, PE, phosphatidylethanolamine; PG, phosphatidylglycerol; TAG, triacylglycerol. Data is reported as mean ± SD or median (interquartile range).

\(1\)

Mann--Whitney test,

\(2\)

Only lipidomic classes where significant differences were found are reported.

Renal Function {#S3.SS3}
--------------

The creatinine clearance was assessed using plasma and urine analysis of creatinine and was performed in 20 subjects in each group as two participants failed to return their sample and three others had urine collection \<1L. Creatinine clearance was similar: 161 ± 44 ml/min and 159 ± 62 ml/min in the group with low and high android fat content, respectively (*p* = 0.90).

Digital Vascular Analysis {#S3.SS4}
-------------------------

Reactive hyperemia index and pulse amplitude tonometry ratio were significantly less in those with higher android fat content compared to those with lower android fat (RHI: 1.64 ± 0.44 vs. 2.26 ± 0.78, *p* = 0.001 and PAT ratio: 0.26 ± 0.44 vs. 0.58 ± 0.40, *p* = 0.013) ([Figure 1](#F1){ref-type="fig"}). Arterial stiffness as assessed by AI\@75 was similar between the two groups ([Figure 1](#F1){ref-type="fig"}).

![Endothelial function as assessed by the reactive hyperemia index (RHI) and Pulse Amplitude Tonometry (PAT ratio) and augmentation index (AI\@75) in subjects with low and high android fat content. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](fphys-10-01162-g001){#F1}

Discussion {#S4}
==========

In this study, we show that for the same level of BMI and fat mass, young overweight males with preferential fat in the android region present with an impaired metabolic profile and endothelial function compared to those with lower android fat content. These differences were observed in the absence of any difference in blood pressure and sympathetic tone.

The group of subjects with higher android fat content presented with reduced insulin sensitivity and decreased glucose tolerance as measured by fasting insulin concentrations and OGTT respectively compared to individuals with lower android fat depot, after correction for BMI. Our study is in line with previous findings demonstrating that excess body fat in abdominal rather than in peripheral fat depot is involved in the development of insulin resistance in adults ([@B32]) and children ([@B4]). This is of particular relevance because decreased insulin sensitivity is thought to be the underlying linkage between obesity, type 2 diabetes and CV disease ([@B34]). Decreased insulin sensitivity in the setting of high android fat depot may reflect structural and functional differences between android and peripheral fat tissue with android tissue possibly expressing higher pro-inflammatory, lipogenic and lipolytic genes and containing higher proportions of saturated fatty acids ([@B26]). We found no difference however between the 2 groups in serum CRP and leptin concentrations and, although serum NEFA tended to be higher in the group with higher android fat, it did not reach significance.

Of note in this study was the finding that endothelial function was significantly lower in the group of young males with higher android fat content. Impaired endothelial function is considered an early marker of atherosclerotic disease, with important clinical implications including cardiac dysfunction, coronary artery disease, hypertension, diabetes, and neurologic disorders, leading to increased mortality and morbidity ([@B17]). Endothelial dysfunction is detectable in overweight children and young adults and develops even after a rapid and modest weight gain of 4 kg ([@B35]). Decreased insulin sensitivity observed in the group with high android fat may have important consequences in the development of endothelial dysfunction and atherosclerosis ([@B28]). The pathway involving decreased endothelial function in this setting of higher android fat remains to be established.

In addition, subjects with higher android fat content were characterized by an abnormal lipid profile in the form of elevated plasma concentration of TG and five other lipidomic classes. Elevated fasting TG levels are a common dyslipidemic feature that accompanies the prediabetic state and is associated with CV risk in young men ([@B41]). Serum TG have previously been reported to be positively associated with android fat in a large study in adults in the general population ([@B27]). Such abnormal serum TG in those with higher android fat content may negatively impact endothelial function as a strong link between serum TG and endothelial function was demonstrated in a large community-based study ([@B15]). Among the many lipid classes, some have been implicated in metabolic and CV disease development in animal models and in humans. Within the system-wide lipid network, [@B39] noted that TAG and PE were most informative for CV disease risk and plasma CER is a significant predictor for CV death beyond currently used lipid markers in patients with coronary artery disease ([@B21]). While it is uncertain why these lipid species are elevated in those with higher android fat, it may add to their elevated CV risk.

Individuals with higher android fat content were characterized by elevated serum UA compared to those with lower android fat. UA has emerged as an important marker of end organ damage ([@B24]) and CV risk ([@B5]). Therefore, increased UA in those with elevated android fat content may be an additional CV risk factor. In line with our findings, a previous study conducted in a large cohort of Chinese subjects indicated that increasing risk of blood pressure outcomes across UA quartiles was most prominent in individuals with abdominal obesity ([@B47]). Hyperuricemia is strongly associated with an increased risk of atherosclerosis and UA has also been shown to induce vascular endothelial dysfunction via oxidative stress and inflammatory responses ([@B33]). However, whether elevated UA in the group of young males with high levels of android fat affects their endothelial function is uncertain because lowering UA fails to improve endothelial function ([@B6]).

While low endothelial function was noticed in individuals with higher fat content, we noticed that the arterial stiffness assessed from the augmentation index from the digits as well as the renal function were not different between subjects with higher or lower android fat content. Both arterial stiffness ([@B8]) and decreased kidney function ([@B29]) have been shown to be affected by fat distribution in older subjects. The young age and absence of cardiometabolic abnormalities in our participants even in the presence of higher android fat may explain the lack of difference. Our results of a lower endothelial function in those with higher android fat depot are different to those of Weil et al. who found that abdominal obesity (assessed with waist circumference) was not associated with greater impairment in endothelial function in overweight and obese adult men ([@B44]). Discrepancies in the findings may be due to differences in subject age, assessment of endothelial function and assessment of abdominal fat content. Our findings are however in agreement with the data from [@B35] who showed that weight gain induced endothelial dysfunction was significantly linked to visceral but not subcutaneous fat gain.

Overweight is a well-recognized risk factor for pre-hypertension and hypertension and studies have suggested that the risk of developing hypertension may be linked to body fatness and body fat distribution ([@B46]; [@B48]). Similarly, excess adiposity is characterized by elevated sympathetic nervous system activity, even in young healthy individuals, which is likely to impact on their CV risk including hypertension development ([@B22]). Given that MSNA was reported to be 55% higher in men with elevated abdominal visceral fat compared with their age, total fat mass, and abdominal subcutaneous fat-matched peers with lower levels ([@B3]), it seems that sympathetic activation may be an important driver mediating CV risk in those with higher abdominal adiposity. Contrary to expectation, we found that MSNA, expressed as bursts incidence was not different between our subjects with high and low android fat content. Of note burst frequency was significantly higher in participants with higher android fat but this increase was no longer noticed after adjusting for the heart rate. This is surprising considering that sympathetic activation to the skeletal muscle is usually observed in the presence of glucose intolerance ([@B40]) and dyslipidemia ([@B23]). Blood pressure and cardiac (vagal) baroreflex function were also found to be similar between the 2 groups suggesting that in this cohort of young overweight males, excess android fat may not further alter hemodynamic control. One exception was noticed for the heart rate which, as noticed above, was higher in those with high android fat content. As the HRV data indicated no differences in cardiac vagal control between the two group, perhaps higher heart rate may reflect preferential sympathetic activation to the heart ([@B10]).

Limitations of the study include the small number of participants and the cross-sectional aspect of our study which does not permit the determination of causality. The EndoPat technique uses pulse volume changes at the fingertips after an occlusion of the brachial artery as an index of endothelial function. Although the method has been validated ([@B19]) it has a higher within-day variability compared to the more traditional method of flow mediated dilation ([@B30]). Dietary habits and physical activity were not assessed in these participants hence we are not able to determine if these factors may have influenced our results. Strengths of the study includes the number of different outcomes assessed with regards to both metabolic and end organ damage as well as direct sympathetic nervous system activity measurements and the use of iDXA.

Conclusion {#S5}
==========

In conclusion, our study indicated that in young overweight but otherwise healthy males, preferential fat depot in the android region was associated with impaired glucose and lipid profile, increased serum UA concentrations and worsening of endothelial function. On the other hand renal function and arterial stiffness were comparable. Contrary to expectation, sympathetic tone as assessed with MSNA and expressed as burst incidence was not elevated in participants with higher android fat content. These data suggest that elevated android fat may confer heightened CV risk and interventions to slow down the development of CV disease should specifically target android fat.
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